Algernon Pharmaceuticals Inc. C.AGN

Alternate Symbol(s): AGNPF

Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N-Dimethyltryptamine (DMT). The Company operates through two segments, which includes the development of repurposed therapeutic drugs in Canada and the facilitation of the Company’s lead drug candidates into off-label phase II clinical trials (humans) in Australia. The Company's pipeline includes NP-251 (Repirinast) and AP-188 (DMT). The Company, through its subsidiary, Algernon NeuroScience Inc., is developing AP-188 (DMT) as a potential treatment for stroke and traumatic brain injury (TBI) recovery. Its NP-251 is being developed as a potential treatment for kidney inflammation and fibrosis.

CSE:AGN - Post by User

Algernon Pharmaceuticals Inc. > Phase 2 Results

<< Previous

Bullboard Posts

Next >>

Comment by Arbourmarkon Mar 09, 2021 8:36am

123 Views

Post# 32750719

RE:RE:RE:RE:RE:RE:Phase 2 Results

Then management should choose their words better. They could have removed "results will be provided shortly after" to something like we anticipate releasing data by end or March or beginning of April.

To me shortly after provides zero clarity.

<< Previous

Bullboard Posts

Next >>

5 steps to mastering risk management in the stock market